Eli Lilly introduced TuneLab, a collaborative platform offering biotech companies free access to its sophisticated artificial intelligence models developed over two decades to predict small molecule and antibody drug properties. In return, participating biotechs share their data to enhance the models. This initiative aims to accelerate drug discovery by providing companies with advanced predictive tools and fostering data-driven innovation. TuneLab marks a major step in leveraging AI to improve pharmaceutical R&D efficiency.